The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Aprea Therapeutics, Inc. | COM | 03836J102 | 99,158 | 2,852,654 | SH | SOLE | 0 | 0 | 0 | ||
Arvinas, Inc. | COM | 04335A105 | 40,300 | 1,000,000 | SH | SOLE | 0 | 0 | 0 | ||
Cabaletta Bio, Inc. | COM | 12674W109 | 26,786 | 3,669,263 | SH | SOLE | 0 | 0 | 0 | ||
Cidara Therapeutics, Inc. | COM | 171757107 | 4,976 | 2,006,511 | SH | SOLE | 0 | 0 | 0 | ||
Crinetics Pharmaceuticals, Inc. | COM | 22663K107 | 27,376 | 1,862,286 | SH | SOLE | 0 | 0 | 0 | ||
Homology Medicines, Inc. | COM | 438083107 | 86,028 | 5,535,919 | SH | SOLE | 0 | 0 | 0 | ||
IDEAYA Biosciences, Inc. | COM | 45166A102 | 14,268 | 3,463,066 | SH | SOLE | 0 | 0 | 0 | ||
scPharmaceuticals Inc. | COM | 810648105 | 24,075 | 3,253,440 | SH | SOLE | 0 | 0 | 0 |